Not sure what you are hoping he is right about. Maybe I missed it, wouldn't be the first time. I guess that if Pfizer continues to fail at targeted cancer drugs, we can hope that they see more value in Ziopharm.
Lewis says that some big drug companies are starting to consider going back to working on safer versions of toxic chemotherapy, an approach his small company is championing.